Search
Strontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnThis kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents instead [A33167, A33168]. … SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168].
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. … Agomelatine is structurally closely related to melatonin.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedIt is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. … Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalAlthough talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use. … In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Betrixaban
go.drugbank.com/drugs/DB12364ApprovedBetrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks … It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286].
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalThis malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnIt was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.
Bemotrizinol
go.drugbank.com/drugs/DB11206ApprovedCompared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212]. … It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application [A19212, A32909].
Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix]. … by preventing intramyometrial growths in the endometrial glands.